Oxford Nanopore Technologies aims to exceed $700 million in annual revenue by 2030, targeting over 15% margin on adjusted earnings and profitability by 2027. The company plans to focus investments on high-value biopharma, clinical testing, and research applications under CEO Francis Van Parys. Recent results showed 10.5% revenue growth to £116.7 million in H1 2026, with strong clinical and biopharma sales, improved gross margin, and reduced losses. Oxford Nanopore also secured a $20 million cross-licensing deal, supporting its growth strategy.
AMD CEO Lisa Su announced that the company's server revenue is projected to grow by more than 80% in the current half-year period. This growth estimate specifically excludes revenue from AMD's AI accelerator business, highlighting strong demand in ot...
BioArctic AB will publish its second quarter financial report for April to June 2026 on August 26, 2026, at 8:00 a.m. CEST. The company will hold a webcast at 9:30 a.m. CEST the same day, where CEO Gunilla Osswald and CFO Anders Martin-Löf will prese...
Interstice Digital has introduced a non-custodial cross-chain swap engine that connects the Canton Network with Ethereum, Solana, and Robinhood Chain, using FalconX to provide liquidity. This engine enables users to swap tokenized assets across these...
Scancell Holdings has received UK regulatory approval to conduct a phase III trial of its lead drug iSCIB1+ for advanced melanoma. The trial will enroll 550 patients across multiple countries, testing iSCIB1+ combined with two immunotherapy drugs aga...
The UK Competition and Markets Authority (CMA) has launched an investigation into Trainline over its use of "drip pricing," where mandatory booking fees are added after the initial ticket price is shown. Fees of up to £2.79 for train bookings and £1....
